Modulation of benzo[a]pyrene-induced p53 DNA activity by acrolein

Carcinogenesis

Volumn 24, Issue 8, 2003, Pages 1401-1406

  Biswal, Shyam ^a   Maxwell, Terrie ^b   Rangasamy, Tirumalai ^a   Kehrer, James P ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACROLEIN; BENZO[A]PYRENE; BUTHIONINE SULFOXIMINE; CARCINOGEN; CIGARETTE SMOKE; DNA; GLUTATHIONE; LUCIFERASE; MONOCLONAL ANTIBODY; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CHEMICAL MODIFICATION; CONTROLLED STUDY; COVALENT BOND; DNA BINDING; EXPOSURE; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LETHAL DOSE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; MODULATION; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; SMOKE; WESTERN BLOTTING;

ACROLEIN; ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; BENZO(A)PYRENE; BLOTTING, WESTERN; BUTHIONINE SULFOXIMINE; DNA, NEOPLASM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GLUTATHIONE; HUMANS; LUCIFERASES; LUNG NEOPLASMS; PRECIPITIN TESTS; PROMOTER REGIONS (GENETICS); TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0041386256     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgg061     Document Type: Article

References (33)

1. Uchida,K. (1999) Current status of acrolein as a lipid peroxidation product. Trends Cardiovasc. Med., 9, 109-113.
2. Furuhata,A., Nakamura,M., Osawa,T. and Uchida,K. (2002) Thiolation of protein-bound carcinogenic aldehyde. An electrophilic acrolein-lysine adduct that covalently binds to thiols. J. Biol. Chem., 277, 27919-27926.
3. Ghilarducci,D.P. and Tjeerdema,R.S. (1995) Fate and effects of acrolein. Rev. Environ. Contam. Toxicol., 144, 95-146.
4. Kehrer,J.P. and Biswal,S.S. (2000) The molecular effects of acrolein. Toxicol. Sci., 57, 6-15.
5. Arrigo,A.P. (1999) Gene expression and the thiol redox state. Free Rad. Biol. Med., 27, 936-944.
6. Rahman,I. and MacNee,W. (1999) Lung glutathione and oxidative stress: implications in cigarette smoke-induced airway disease. Am. J. Physiol., 277, L1067-1088.
7. Rahman,Q., Abidi,P., Afaq,F., Schiffmann,D., Mossman,B.T., Kamp,D.W. and Athar,M. (1999) Glutathione redox system in oxidative lung injury. Crit. Rev. Toxicol., 29, 543-568.
8. Rahman,I. and MacNee,W. (2000) Oxidative stress and regulation of glutathione in lung inflammation. Eur. Respir. J., 16, 534-554.
9. Rahman,I. (1999) Inflammation and the regulation of glutathione level in lung epithelia] cells. Antioxid. Redox Signal, 1, 425-447.
10. Bojes,H.K., Feng,X., Kehrer,J.P. and Cohen,G.M. (1999) Apoptosis in hematopoietic cells (FL5.12) caused by interleukin-3 withdrawal: relationship to caspase activity and the loss of glutathione. Cell Death Differ., 6, 61-70.
11. Horton,N.D., Biswal,S.S., Corrigan,L.L., Bratta,J. and Kehrer,J.P. (1999) Acrolein causes inhibitor kappaB-independent decreases in nuclear factor kappaB activation in human lung adenocarcinoma. (A549) cells. J. Biol. Chem., 274, 9200-9206.
12. Biswal,S., Acquaah-Mensah,G., Datta,K., Wu,X. and Kehrer,J.P. (2002) Inhibition of cell proliferation and AP-1 activity by acrolein in human A549 lung adenocarcinoma cells due to thiol imbalance and covalent modifications. Chem. Res. Toxicol., 15, 180-186.
13. Hussain,S.P., Hofseth,L.J. and Harris,C.C. (2001) Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. Lung Cancer, 34 (suppl. 2), S7-S15.
14. Fraiser,L., Kanekal,S. and Kehrer,J.P. (1991) Cyclophosphamide toxicity: characterizing and avoiding the problem. Drugs, 42, 781-795.
15. Cohen,S.M., Garland,E.M., St John,M., Okamura,T. and Smith,R.A. (1992) Acrolein initiates rat urinary bladder carcinogenesis. Cancer Res., 52, 3577-3581.
16. Satoh,K., Hayakari,M., Ookawa,K., Satou,M., Aizawa,S., Tanaka,M., Hatayama,I., Tsuchida,S. and Uchida,K. (2001) Lipid peroxidation end products-responded induction of a preneoplastic marker enzyme glutathione S-transferase P-form (GST-P) in rat liver on admistration via the portal vein. Mutat. Res., 483, 65-72.
17. Takabe,W., Niki,E., Uchida,K., Yamada,S., Satoh,K. and Noguchi,N. (2001) Oxidative stress promotes the development of transformation: involvement of a potent mutagenic lipid peroxidation product, acrolein. Carcinogenesis, 22, 935-941.
18. Ramet,M., Castren,K., Jarvinen,K., Pekkala,K., Turpeenniemi-Hujanen,T., Soini,Y., Paakko,P. and Vahakangas,K. (1995) p53 protein expression is correlated with benzo[a]pyrene-DNA adducts in carcinoma cell lines. Carcinogenesis, 16, 2117-2124.
19. Noble,J.R., Willetts,K.E., Mercer,W.E. and Reddel,R.R. (1992) Effects of exogenous wild-type p53 on a human lung carcinoma cell line with endogenous wild-type p53. Exp. Cell Res., 203, 297-304.
20. Neuschwander-Tetri,B.A. and Roll,F.J. (1989) Glutathione measurement by high-performance liquid chromatography separation and fluorometric detection of the glutathione-orthophthalaldehyde adduct. Anal. Biochem., 179, 236-241.
21. Pei,X.H., Nakanishi,Y., Takayama,K., Bai,F. and Hara,N. (1999) Benzo[a]pyrene activates the human p53 gene through induction of nuclear factor kappaB activity. J. Biol. Chem., 274, 35240-35246.
22. Reisman,D., Greenberg,M. and Rotter,V. (1988) Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1. Proc. Natl Acad. Sci. USA, 85, 5146-5150.
23. Raman,V., Martensen,S.A., Reisman,D., Evron,E., Odenwald,W.F., Jaffee,E., Marks,J. and Sukumar,S. (2000) Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature, 405, 974-978.
24. Tirumalai,R., Rajesh Kumar,T., Mai,K.H. and Biswal,S. (2002) Acrolein causes transcriptional induction of phase II genes by activation of Nrf2 in human lung type II epithelial (A549) cells. Toxicol. Lett., 132, 27-36.
25. Uchida,K., Kanematsu,M., Morimitsu,Y., Osawa,T., Noguchi,N. and Niki,E. (1998) Acrolein is a product of lipid peroxidation reaction. Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. J. Biol. Chem., 273, 16058-16066.
26. Stewart,Z.A. and Pietenpol,J.A. (2001) p53 Signaling and cell cycle checkpoints. Chem. Res. Toxicol., 14, 243-263.
27. Meek,D.W. (1999) Mechanisms of switching on p53: a role for covalent modification? Oncogene, 18, 7666-7675.
28. Hainaut,P. and Milner,J. (1993) Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res., 53, 4469-4473.
29. Jayaraman,L., Murthy,K.G., Zhu,C., Curran,T., Xanthoudakis,S. and Prives,C. (1997) Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev., 11, 558-570.
30. Pearson,G.D. and Merrill,G.F. (1998) Deletion of the Saccharomyces cerevisiae TRR1 gene encoding thioredoxin reductase inhibits p53-dependent reporter gene expression. J. Biol. Chem., 273, 5431-5434.
31. Moos,P.J., Edes,K., Cassidy,P., Massuda,E. and Fitzpatrick,F.A. (2003) Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J. Biol. Chem., 278, 745-750.
32. Havre,P.A., O'Reilly,S., McCormick,J.J. and Brash,D.E. (2002) Transformed and tumor-derived human cells exhibit preferential sensitivity to the thiol antioxidants, N-acetyl cysteine and penicillamine. Cancer Res., 62, 1443-1449.
33. Liu,M., Pelling,J.C., Ju,J., Chu,E. and Brash,D.E. (1998) Antioxidant action via p53-mediated apoptosis. Cancer Res., 58, 1723-1729